All relevant data are within the paper and its Supporting Information files.

Introduction {#sec006}
============

Obstructive sleep apnea syndrome (OSAS) is a common but often unrecognized disorder \[[@pone.0115625.ref001]\]. It is characterized by recurrent episodes of intermittent hypoxemia and arousal during sleep, caused by repeated episodes of upper airway collapse \[[@pone.0115625.ref002],[@pone.0115625.ref003]\]. Overnight polysomnography (PSG) is considered the gold standard for its diagnosis. There has been increasing recognition that OSAS, due to its hypoxemia, is associated with a higher incidence of many neurological problems, including stroke, cognitive decline, depression, headaches, peripheral neuropathy, and non-arteritic ischemic optic neuropathy (NAION) \[[@pone.0115625.ref004],[@pone.0115625.ref005],[@pone.0115625.ref006],[@pone.0115625.ref007],[@pone.0115625.ref008]\].

Glaucoma is an optic neuropathy, in which tissue damage occurs at the level of the optic nerve head, resulting in a characteristic alteration of its appearance, as well as visual field disturbances \[[@pone.0115625.ref009]\]. Most of these conditions are related to elevated intraocular pressure (IOP), which can also damage the optic nerve directly \[[@pone.0115625.ref010]\]. However, given that at least some glaucoma patients have low or normal intraocular pressure, other systemic conditions, such as diabetes, cardiovascular disease, and obesity, may also be relevant \[[@pone.0115625.ref011],[@pone.0115625.ref012]\].

Whether there is an association between sleep apnea and glaucomatous neuropathy has long been controversial in the literature. Some studies have confirmed the existence of a relationship between sleep apnea and normal-tension glaucoma (NTG), and/or open-angle glaucoma (OAG) \[[@pone.0115625.ref013],[@pone.0115625.ref014],[@pone.0115625.ref015],[@pone.0115625.ref016]\]. However, other studies have shown no relationship \[[@pone.0115625.ref017],[@pone.0115625.ref018],[@pone.0115625.ref019],[@pone.0115625.ref020]\]. Thus, we performed this meta-analysis to evaluate whether there is a significant positive association between OSAS and the prevalence of glaucoma.

Materials and Methods {#sec007}
=====================

Data Sources and Searches {#sec008}
-------------------------

This meta-analysis was carried out according to the PRISMA guidelines \[[@pone.0115625.ref021]\] ([S1 PRISMA Checklist](#pone.0115625.s001){ref-type="supplementary-material"}). Two investigators (Yuhua Shi and Kaiming Su) performed a comprehensive literature search, using Embase and PubMed, for related literature published before March 2014. The following terms were used: 1) glaucoma, optic neuropathy, 2) sleep apnea, sleep dysfunction, sleep disordered, OSAS, SAS or OSASHS. Literature language and literature type were not restricted.

We first performed an initial screening of all searched abstracts and subsequently selected the relevant full texts for further investigation. We also searched for "related articles" in PubMed. To find more articles, a manual search of the reference lists of relevant original and review articles was also performed. The two reviewers (Yuhua Shi and Kaiming Su) carried out the initial screening independently; any disagreements were discussed among the authors and resolved by consensus.

Inclusion and Exclusion Criteria {#sec009}
--------------------------------

Any study that met all of the following criteria was included in the quantitative analysis (meta-analysis): (1) the study was of an observational design (cross-sectional, case-control, or cohort studies) and concerned an association between OSAS and glaucoma, (2) clear diagnostic criteria for OSAS were established, (3) diagnostic criteria for glaucoma were also established, (4) OSAS and glaucoma could be used as an outcome in the analysis, and (5) the study included an effective control group.

Studies that met the above criteria with the exception of item 5 (no effective control group) were excluded from the quantitative analysis but included in the review. Case reports and literature reviews were also excluded from the review.

Data Extraction and Quality Assessment {#sec010}
--------------------------------------

Information was extracted from all eligible studies by two independent investigators. Differences in the information extracted were discussed among the authors and resolved by consensus. The recorded information for cross-sectional and case-control studies included the name of the first author, publication year, nationality, study design, participant selection, age, type(s) of glaucoma, total numbers of cases and controls, methods for the diagnosis of glaucoma, method used to assess OSAS, adjustment for covariates and the authors' conclusions. For cohort studies, we also collected the follow-up period.

Because there is no consensus as to the 'best' standardized method for assessing the quality of observation studies \[[@pone.0115625.ref022]\], we designed a five-item scoring scale (each item scoring 0 or 1; 1 being better) \[[@pone.0115625.ref022],[@pone.0115625.ref023]\]. The items on the integer scale were representativeness of the cases, whether the assessment of glaucoma was appropriate, whether the assessment of sleep apnea was objective, whether sleep apnea severity was assessed, and controls for confounding. Scores of 0--3 were evaluated as 'low' quality while 4 or 5 was considered to indicate 'high' quality \[[@pone.0115625.ref022],[@pone.0115625.ref023]\]. Two reviewers, Yuhua Shi and Kaiming Su, assessed the quality independently while blinded to each other's evaluations; disagreements or uncertainties were then settled by discussion.

Statistical Methods {#sec011}
-------------------

In this study, the heterogeneity between studies determined the model (a fixed-effects or a random-effects model) used for the meta-analysis. A statistical test for heterogeneity was performed with the I^2^ statistic (values of 25%, 50%, and 75% were considered to represent low, medium, and high degrees of heterogeneity, respectively) and the Q test (heterogeneity was considered statistically significant when P \< 0.10). When there was significant heterogeneity (I^2^\> 50%), a random-effects model was used to evaluate the pooled OR; otherwise, we used a fixed-effects model.

In cross-sectional and case-control studies, the odds ratio with 95% confidence intervals was used to evaluate the association between OSAS and glaucoma; combined ORs were obtained using the Mantel-Haenszel method. For cohort studies, we calculated the hazard ratio (HR) of glaucoma with the respective 95% CI, if possible. To further evaluate the stability of the results, sensitivity analysis was performed by sequentially excluding each study.

The meta-analysis was performed using Review Manager (ver. 5.2.0). A P value \< 0.05 was considered to indicate statistical significance.

Results {#sec012}
=======

Literature Search Results and the Characteristics of the Included Studies {#sec013}
-------------------------------------------------------------------------

Both investigators agreed on the results of study selection (inclusion/exclusion). The strategies for study identification and study selection are shown in [Fig. 1](#pone.0115625.g001){ref-type="fig"}. There were 23 studies focusing on the association between OSAS and glaucoma, but only 16, with a total of 2,278,832 participants, were included in the analysis according to the criteria above ([Table 1](#pone.0115625.t001){ref-type="table"}). These consisted of one retrospective cohort study \[[@pone.0115625.ref014]\], six case-control studies with OSAS as exposure \[[@pone.0115625.ref015],[@pone.0115625.ref017],[@pone.0115625.ref018],[@pone.0115625.ref019],[@pone.0115625.ref024],[@pone.0115625.ref025]\], and nine cross-sectional studies comparing glaucoma in OSAS and non-OSAS groups \[[@pone.0115625.ref013],[@pone.0115625.ref016],[@pone.0115625.ref020],[@pone.0115625.ref026],[@pone.0115625.ref027],[@pone.0115625.ref028],[@pone.0115625.ref029],[@pone.0115625.ref030],[@pone.0115625.ref031]\] ([Table 1](#pone.0115625.t001){ref-type="table"}). In a study reporting the prevalence of both open-angle glaucoma (OAG) and normal-tension glaucoma (NTG) in sleep apnea patients, data for NTG were excluded because the two sets of data overlapped and could not be merged, while the sample size for OAG was considerably larger than that for NTG \[[@pone.0115625.ref028]\].

![Flow chart of the procedure for identifying studies and the results thereof.](pone.0115625.g001){#pone.0115625.g001}

10.1371/journal.pone.0115625.t001

###### The 23 observational studies investigating associations between obstructive sleep apnea and glaucoma.

![](pone.0115625.t001){#pone.0115625.t001g}

  No.                                    Reference                    Nationality& Region   Participants                                Mean Age(years)Case/control   Types of Glaucoma   Glaucoma diagnosis      OSAS diagnosis                  Glaucoma in OSAS                   Glaucoma in control                        OSAS in Glaucoma   OSAS in control   Significant Association?   Adjustment for covariates                                                                                                                                                                                                                      Scoring   Exclusion reason
  -------------------------------------- ---------------------------- --------------------- ------------------------------------------- ----------------------------- ------------------- ----------------------- ------------------------------- ---------------------------------- ------------------------------------------ ------------------ ----------------- -------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------- --------------------------------------------------
  **Included cohort Studies**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  1                                      \[[@pone.0115625.ref014]\]   Taiwan                Clinical Database                           66.7/67.2                     OAG                 Database record         Database PSG record             114/1012                           410/6072                                                                        YES                        Age, sex, urbanization level, year of index date, hypertension, diabetes, coronary heart disease, hyperlipidemia, obesity, renal disease, migraine, and hypothyroidism                                                                         4         /
  **Included case-control Studies**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  2                                      \[[@pone.0115625.ref015]\]   France                OAG patients and control                    \>40                          OAG                 Eye examination,        Sleep questionnaire             /                                  /                                          58/212             39/218            YES                        /                                                                                                                                                                                                                                              3         /
  3                                      \[[@pone.0115625.ref024]\]   USA                   NTG patients and control                    40--60                        NTG                 Database record,ICD-9   Sleep history, PSG              /                                  /                                          2/37               1/30              YES                        /                                                                                                                                                                                                                                              3         /
  4                                      \[[@pone.0115625.ref017]\]   USA                   OAG patients and control                    69/69                         OAG                 Database record,ICD-9   Database record, ICD-9          /                                  /                                          7/667              32/6667           NO                         Age, diabetes, lipid metabolism disorders, hypertension, cardiovascular disease, cerebrovascular disease, arterial disease, and migraines                                                                                                      4         /
  5                                      \[[@pone.0115625.ref018]\]   Australia             OAG patients and control                    71/70                         OAG                 Eye examination         Oximetry monitoring, ODI \>20   /                                  /                                          9/52               7/60              NO                         /                                                                                                                                                                                                                                              4         /
  6                                      \[[@pone.0115625.ref019]\]   India                 OAG and NTG and control                     40--60                        OAG,NTG             Eye examination         Sleep history, PSG              /                                  /                                          4/40               1/40              NO                         /                                                                                                                                                                                                                                              3         /
  7                                      \[[@pone.0115625.ref025]\]   Turkey                NTG patients and control                    53--78                        NTG                 Eye examination         PSG, AHI≥20                     /                                  /                                          10/24              3/24              YES                        /                                                                                                                                                                                                                                              4         /
  **Included cross-sectional Studies**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  8                                      \[[@pone.0115625.ref013]\]   Italy                 Diagnosed OSA, Consecutively with control   74.5/75                       NTG                 Eye examination         PSG, AHI≥10                     3/51                               0/40                                       /                  /                 YES                        /                                                                                                                                                                                                                                              3         /
  9                                      \[[@pone.0115625.ref031]\]   Thailand              Suspected OSAS, Consecutively               75/54.7                       OAG,NTG             Eye examination         PSG, AHI≥10                     6/44                               3/42                                       /                  /                 NO                         /                                                                                                                                                                                                                                              3         /
  10                                     \[[@pone.0115625.ref026]\]   China                 Suspected OSAS, Consecutively               67.7/72                       OAG,NTG             Eye examination         PSG, AHI\>5                     4/31                               0/25                                       /                  /                 YES                        /                                                                                                                                                                                                                                              2         /
  11                                     \[[@pone.0115625.ref020]\]   UK                    Suspected OSA, Consecutively                84.3/65.4                     OAG,NTG             Eye examination         PSG, ODI≥5                      3/89                               1/26                                       /                  /                 NO                         /                                                                                                                                                                                                                                              3         /
  12                                     \[[@pone.0115625.ref027]\]   Taiwan                Suspected OSA, Consecutively                76.7/63.1                     NTG                 Eye examination         PSG, AHI≥5                      12/209                             0/38                                       /                  /                 YES                        /                                                                                                                                                                                                                                              4         /
  13                                     \[[@pone.0115625.ref016]\]   USA                   Medical database                            /                             Nonspecific         Database record         Database record                 228/2725                           3410/68235                                 /                  /                 YES                        /                                                                                                                                                                                                                                              3         /
  14                                     \[[@pone.0115625.ref028]\]   USA                   Medical database                            \>40                          OAG,                Billing records         Billing records                 OAG: 4557/151633; NTG:342/156308   OAG: 50533/2030682; NTG:154330/209916555   /                  /                 NO                         Age, sex, race, region of residence within the US, education level, household net worth, and some medical and ocular conditions including diabetes mellitus, hypertension, obesity, cataract, diabetic retinopathy, and macular degeneration   4         Data of NTG were excluded because of overlapping
  15                                     \[[@pone.0115625.ref030]\]   Spain                 Suspected OSA, Consecutively                79.5/72                       OAG,NTG             Eye examination         PSG, AHI≥10                     16/202                             0/25                                       /                  /                 YES                        /                                                                                                                                                                                                                                              3         /
  16                                     \[[@pone.0115625.ref029]\]   France                Medical database                            63.25/61.82                   /                   Database record         Database record                 240/6754                           89/2826                                    /                  /                 NO                         Age, sex, height, weight, body mass index, arterial hypertension, tobacco consumption, high cholesterol levels, high triglyceride levels, and thyroid dysfunction.                                                                             4         /
  **Excluded Studies**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  17                                     \[[@pone.0115625.ref032]\]   Switzerland           Diagnosed Glaucoma patients                 39--81                        NTG                 Eye examination         PSG, RDI \>10                   /                                  /                                          7/16               /                 YES                        /                                                                                                                                                                                                                                              /         No effective control
  18                                     \[[@pone.0115625.ref033]\]   France                Diagnosed Glaucoma patients                 57.85                         OAG NTG             Eye examination         Sleep history, PSG              /                                  /                                          15/31              /                 YES                        /                                                                                                                                                                                                                                              /         No effective control
  19                                     \[[@pone.0115625.ref034]\]   Switzerland           OSAS, Consecutively                         88.4                          OAG,NTG             Eye examination         PSG, RDI\>10                    5 /69                              /                                          /                  /                 YES                        /                                                                                                                                                                                                                                              /         No effective control
  20                                     \[[@pone.0115625.ref035]\]   Israel                Diagnosed OSAS, Consecutively               83.3                          OAG                 Eye examination         PSG, RDI\>10                    5/228                              /                                          /                  /                 NO                         /                                                                                                                                                                                                                                              /         No effective control
  21                                     \[[@pone.0115625.ref036]\]   Hong Kong             Diagnosed OSAS, Consecutively               86.11/86.66                   /                   Eye examination         PSG, AHI≥20                     3/82(eyes)                         2/68(eyes)                                 /                  /                 YES                        /                                                                                                                                                                                                                                              /         Not enough data
  22                                     \[[@pone.0115625.ref037]\]   USA                   Suspected OSA                               65                            OAG NTG             Eye examination         PSG, AHI\>15                    27/100                             /                                          /                  /                 YES                        /                                                                                                                                                                                                                                              /         No effective control
  23                                     \[[@pone.0115625.ref038]\]   Iran                  Diagnosed OSAS                              51.77                         OAG                 Eye examination         PSG, AHI\>5                     9/90                               /                                          /                  /                 YES                        /                                                                                                                                                                                                                                              /         No effective control

OSAS, obstructive sleep apnea syndrome; OAG, open-angle glaucoma; NTG, normal-tension glaucoma; ICD-9, International Classification of Diseases, 9th edition

PSG, polysomnography; ODI, oxygen desaturation index; AHI, apnea hypopnea index.

The remaining seven studies \[[@pone.0115625.ref032],[@pone.0115625.ref033],[@pone.0115625.ref034],[@pone.0115625.ref035],[@pone.0115625.ref036],[@pone.0115625.ref037],[@pone.0115625.ref038]\] were excluded. One study had insufficient data for extraction; it reported the number of eyes with glaucoma but not the number of patients \[[@pone.0115625.ref036]\]. The other six were excluded because they included no effective control group; those articles concluded with or without a significant association between glaucoma and OSAS were based only on a high or low prevalence of glaucoma (or OSAS) in patients with OSAS (or glaucoma). For example, one article reported that the prevalence of glaucoma in patients with sleep apnea was 7.2%, which is higher than the 2% expected in the general population \[[@pone.0115625.ref034]\].

Regarding the diagnostic methods for glaucoma, the included reports used two criteria; 10 used systematic eye examinations, including visual field, optic nerve head cupping, anterior chamber angle, and intraocular pressure \[[@pone.0115625.ref013],[@pone.0115625.ref015],[@pone.0115625.ref018],[@pone.0115625.ref019],[@pone.0115625.ref020],[@pone.0115625.ref025],[@pone.0115625.ref026],[@pone.0115625.ref027],[@pone.0115625.ref030],[@pone.0115625.ref031]\], while 6 were based on database or billing records \[[@pone.0115625.ref014],[@pone.0115625.ref016],[@pone.0115625.ref017],[@pone.0115625.ref024],[@pone.0115625.ref028],[@pone.0115625.ref029]\]. Regarding the diagnostic criteria for OSAS, nine used objective evaluations, such as PSG and oximetry monitoring \[[@pone.0115625.ref013],[@pone.0115625.ref018],[@pone.0115625.ref019],[@pone.0115625.ref020],[@pone.0115625.ref025],[@pone.0115625.ref026],[@pone.0115625.ref027],[@pone.0115625.ref030],[@pone.0115625.ref031]\], five were based on database or billing records \[[@pone.0115625.ref014],[@pone.0115625.ref016],[@pone.0115625.ref017],[@pone.0115625.ref024],[@pone.0115625.ref029]\], and one was based only on a sleep questionnaire \[[@pone.0115625.ref015]\].

The study population and data source were from a single hospital in 12 studies (6 case-control studies and 6 cross-sectional studies). The patients in five case-control studies were diagnosed glaucoma patients at an eye clinic \[[@pone.0115625.ref015],[@pone.0115625.ref018],[@pone.0115625.ref019],[@pone.0115625.ref024],[@pone.0115625.ref025]\]; the other case-control study was from a hospital-based database \[[@pone.0115625.ref017]\]. In contrast, all patients in the cross-sectional studies with suspected OSAS were from sleep centers \[[@pone.0115625.ref013],[@pone.0115625.ref020],[@pone.0115625.ref026],[@pone.0115625.ref027],[@pone.0115625.ref030],[@pone.0115625.ref031]\]. Data for the four other included studies were from a database that contained information on patients from several hospitals.

Two of the six case-control studies matched by age or gender \[[@pone.0115625.ref017],[@pone.0115625.ref025]\], three case-control studies reported no difference between cases and controls in age, gender, and/or body mass index (BMI) in the design \[[@pone.0115625.ref015],[@pone.0115625.ref018],[@pone.0115625.ref024]\]; two cross-sectional studies \[[@pone.0115625.ref027],[@pone.0115625.ref029]\] reported associations between OSAS and glaucoma according to OSAS severity. The quality score for the cohort study was 4. The mean quality scores of the case-control studies and cross-sectional studies were 3.5 (range, 2--4) and 3.2 (range, 2--4), respectively. A detailed assessment of the quality of the included studies is provided in [S1 Table](#pone.0115625.s002){ref-type="supplementary-material"}.

Pooled-analysis Results {#sec014}
-----------------------

**Cohort studies.** Because only one cohort study was included, a meta-analysis was not performed for this series. The population-based retrospective cohort study included 1012 OSAS patients and 6072 controls, aged 40 years or older. After adjusting for several confounders, such as monthly income, place of residence, diabetes, cardiovascular disease, and obesity, the hazard ratio for OAG within the 5-year period for subjects with OSAS was 1.67 (95% CI = 1.30--2.17; P\<0.001) \[[@pone.0115625.ref014]\].

**Case-control studies.** Of the six case-control studies, which involved 1032 glaucoma patients and 7039 controls, two showed positive associations between OSAS and glaucoma, while four showed no association. Thus, we performed a pooled analysis to assess the overall results. A fixed-effects model was used for the pooled analysis because no statistical heterogeneity was found among the studies (χ^2^ = 2.60, I^2^ = 0%, P = 0.76). The results showed a significant relationship between glaucoma and OSAS (pooled OR = 1.96, 95%CI = 1.37--2.80; P = 0.0002; [Fig. 2](#pone.0115625.g002){ref-type="fig"}).

![Forest plot of case-control studies showing the odds ratios (ORs) with 95% confidence intervals (95% CI) of OSAS for participants with and without glaucoma.\
The squares and horizontal lines represent the study-specific ORs and 95% CIs. The sizes of the squares reflect the statistical weights of the studies. The pooled OR is indicated by a diamond (fixed-effect model).](pone.0115625.g002){#pone.0115625.g002}

Sensitivity analysis: The result of the heterogeneity test and the significance of the pooled OR were not greatly influenced by the omission of a single study (Onen 2000, weight: 65.3%) in which the OSAS diagnosis was based only on a questionnaire (χ^2^ = 1.96, I^2^ = 0%; P = 0.74; pooled OR = 2.40, 95% CI = 1.38--4.18, P = 0.002). We also evaluated the pooled OR for the remaining studies by excluding each study sequentially, which produced a range from 1.83 (95% CI = 1.17--2.65; P = 0.001) to 2.40 (95% CI = 1.38--4.18; P = 0.002), also indicating a 'stable' result for the association.

Subgroup analysis: Subjects in the studies were from various geographical regions, and racial differences have been reported in patients with OSAS. Thus, a subgroup analysis of the case control studies according to region was also conducted. The pooled ORs of the studies from United States + Europe \[[@pone.0115625.ref015],[@pone.0115625.ref017],[@pone.0115625.ref024]\] and other countries \[[@pone.0115625.ref018],[@pone.0115625.ref019],[@pone.0115625.ref025]\] were 1.80 (95% CI = 1.21--2.69, P = 0.004) and 2.64 (95% CI = 1.21--5.77, P = 0.02), respectively. Thus, both comparisons showed a positive association between OSAS and glaucoma.

**Cross-sectional studies.** In nine cross-sectional studies, glaucoma was present in 5,069 of 161,738 patients with OSAS and in 54,036 of 2,101,939 patients without OSAS. Because the heterogeneity test showed medium-to-high heterogeneity among the individual studies (heterogeneity test χ^2^ = 29.26, I^2^ = 73%, P = 0.0003), a pooled analysis was performed using a random-effects model. The overall pooled OR for glaucoma was 1.41 (95% CI = 1.11--1.79, P = 0.006) in the OSAS group versus the non-OSAS group ([Fig. 3](#pone.0115625.g003){ref-type="fig"}).

![Forest plot of cross-sectional studies showing the odds ratios (ORs) with 95% confidence intervals (95% CI) of glaucoma for participants with and without OSAS. **The squares and horizontal lines represent the study-specific ORs and 95% CIs.**\
The sizes of the squares reflect the statistical weights of the studies. The pooled OR is indicated by a diamond (random-effect model).](pone.0115625.g003){#pone.0115625.g003}

Sensitivity analysis: To explore the potential sources of heterogeneity observed in this analysis, we excluded each study sequentially to determine its effect on the main summary estimate. The pooled OR ranged from 1.21(95%CI = 1.18--1.28, P\<0.0001) to 1.55 (95% CI = 1.12--2.13, P = 0.007). After removing the study of Boyle 2011 \[[@pone.0115625.ref016]\], which enrolled patients from a veterans' electronic medical database, the variation across the studies disappeared and the I^2^ statistic dropped from 73% to 0% (heterogeneity test χ^2^ = 5.29, P = 0.62). This study suggested that the diagnosis rate of glaucoma was 8.4% in patients with sleep apnea and 5% in those without, markedly higher than in the two other large-sample studies. The pooled OR of glaucoma in the remaining eight studies was 1.28 (95% CI = 1.18--1.25, P\<0.00001).

Subgroup analysis: Because the diagnosis of OSAS in each of the three large-sample-size studies \[[@pone.0115625.ref016],[@pone.0115625.ref028],[@pone.0115625.ref029]\] was based on billing codes or medical records, not polysomnography, a subgroup analysis was performed of the six smaller-sample-size studies \[[@pone.0115625.ref013],[@pone.0115625.ref020],[@pone.0115625.ref026],[@pone.0115625.ref027],[@pone.0115625.ref030],[@pone.0115625.ref031]\], which consequently had wider confidence intervals and in which all diagnoses of OSAS were based on objective measurements. The pooled analysis of these studies also demonstrated a significant association between OSAS and glaucoma (χ^2^ = 2.25, I^2^ = 0, p = 0.81; pooled OR = 3.15, 95%CI = 1.26--7.90, P = 0.01; [Fig. 4](#pone.0115625.g004){ref-type="fig"}).

![Forest plot of six cross-sectional studies with small sample sizes showing the odds ratios (ORs) with 95% confidence intervals (95% CI) of glaucoma for participants with and without OSAS.\
The squares and horizontal lines represent the study-specific ORs and 95% CIs. The sizes of the squares reflect the statistical weights of the studies. The pooled OR is indicated by a diamond (fixed-effect model).](pone.0115625.g004){#pone.0115625.g004}

A subgroup analysis of the cross-sectional studies according to region was also conducted. The pooled ORs of the studies from the United States/Europe \[[@pone.0115625.ref013],[@pone.0115625.ref016],[@pone.0115625.ref020],[@pone.0115625.ref028],[@pone.0115625.ref029],[@pone.0115625.ref030]\] and Asian countries \[[@pone.0115625.ref026],[@pone.0115625.ref027],[@pone.0115625.ref031]\] in the cross-sectional studies were 1.36 (95% CI = 1.06--1.75, P = 0.1; τ^2^ = 26.31, I^2^ = 81%; P \<0.0001) and 3.39 (95% CI = 1.06--10.81, P = 0.04; χ^2^ = 0.87, I^2^ = 0%; P = 0.65), respectively. Thus, both showed a positive association between OSAS and glaucoma.

Confounding factors {#sec015}
-------------------

Only four of the studies reported their results after adjusting for confounding factors. One was the cohort study \[[@pone.0115625.ref014]\] that showed a significant association, as described above. The second was the case-control study of Girkin et al. \[[@pone.0115625.ref017]\]. After adjusting for some systemic diseases, such as diabetes, lipid metabolism disorders, hypertension, and cardiovascular disease, a conditional logistic regression analysis showed no significant relationship between glaucoma and sleep apnea (unadjusted OR, 2.20; 95% CI, 0.967--5.004; P = 0.06; adjusted OR, 1.80; 95% CI, 0.76--4.23; P = 0.18). The two other studies were of cross-sectional design \[[@pone.0115625.ref028],[@pone.0115625.ref029]\]. Both showed no significant association between the two conditions after adjusting for several confounding systemic diseases. The reported adjusted ORs were 1.01 (95% CI, 0.98--1.05) \[[@pone.0115625.ref028]\] and 1.13 (95% CI, 0.87--1.47) \[[@pone.0115625.ref029]\], respectively.

Due to the limited number of studies involved and their marked heterogeneity (one cohort, one case-control, two cross-sectional), it was inappropriate to combine their data. Thus, no meta-regression was performed.

Pooled data from all 16 observational studies were also not analyzed, mainly because the subjects in the cross-sectional and cohort studies were usually suspected OSAS patients in sleep centers or a large medical database, while patients in the case-control studies were usually from an eye clinic. The biases in patient selection in those studies resulted inconsiderable clinical variability and heterogeneity, making further statistical analyses difficult.

It should be emphasized that the reported pooled estimates for the case-control studies and cross-sectional studies were based on unadjusted ORs, and the findings from studies that adjusted for potential confounders were inconsistent.

Discussion {#sec016}
==========

Determining an association between OSAS and glaucoma could be meaningful from a public health point of view, given that both are common medical disorders. This meta-analysis of six case-control and nine cross-sectional studies confirmed a statistically significant association between OSAS and glaucoma, consistent with a previously reported retrospective cohort study. Given that no prospective study was included, and the pooled results in this study represent unadjusted estimates, which are likely to be confounded by other risk factors, these results should be confirmed in further studies.

Our analysis included five studies based on patient databases \[[@pone.0115625.ref014],[@pone.0115625.ref016],[@pone.0115625.ref017],[@pone.0115625.ref028],[@pone.0115625.ref029]\], in which the sample sizes were very large, and the diagnosis of sleep apnea was from billing records, sleep history, or disease classification diagnosis codes, but not polysomnography. Because glaucoma directly affects vision, whereas symptoms of sleep apnea may not be as obvious and are prone to be neglected by potential patients, the rate of undiagnosed sleep apnea in a database of patients should be much higher than that of glaucoma, which may introduce selection bias. However, because of their very large sample sizes, these studies were included in the analysis. Additionally, to reduce the interference, we also performed subgroup analyses of those studies with an objective OSAS diagnosis, but with smaller sample size and, consequently, wider confidence intervals. A significant association between OSAS and glaucoma was also found in these results.

It has been reported that the clinical characteristics of patients with OSAS differ according to ethnicity \[[@pone.0115625.ref039]\]. For example, past studies have found that the relationship between hypertension and symptoms of OSAS may be mediated by ethnicity and race. In this study, subgroup analyses showed that the significant association between OSAS and glaucoma was unaffected by the study region. However, due to the limited number of included studies, whether these results are applicable to all races/ethnicities should be investigated further.

A meta-analysis including observational studies cannot 'prove' causation. However, two theories, a vascular theory and a mechanical theory, can explain the potential association between OSAS and glaucoma \[[@pone.0115625.ref014],[@pone.0115625.ref040]\]. The vascular theory postulates that the upper airway collapse during sleep in OSAS patients would lead to repeated or prolonged episodes of hypoxia, which may reduce the oxygen supply to the optic nerve, and subsequently lead to optic neuropathy. The mechanical theory considers that OSAS has the potential to raise the intraocular pressure through changes in sleep architecture and through an increase in sympathetic tone; this raised intraocular pressure will lead to axon damage at the optic nerve, and eventually cause glaucoma. Other theories, including inflammation, oxidative stress, and hypercapnia, have also been suggested to explain the association between glaucoma and sleep apnea \[[@pone.0115625.ref041],[@pone.0115625.ref042]\].

Because of the limited number of related studies, the issue of confounding could not be examined by meta-regression in this study. A meta-analysis should be carried out using 'raw' data, and thus the pooled odds ratios represent unadjusted estimates, which are likely to be heavily confounded by other risk factors such as age, gender, and hypertension. While the apparent association between OSAS and glaucoma may be of interest in its own right, any attempt to explore this relationship further would seem to be incomplete without examining the roles of potential confounders. In fact, patients with OSAS have significantly higher risks of *all* comorbidities considered \[[@pone.0115625.ref005]--[@pone.0115625.ref007]\]. Thus, OSAS may simply be a marker of poor (vascular, obesity) health, and not necessarily an independent risk factor for glaucoma.

Two other limitations of this meta-analysis should also be considered. First, none of the studies selected their participants randomly; most were based on patients attending a clinic, Thus, selection bias may exist. Second, due to the limited number of studies involved relating to OSAS and glaucoma, only two studies included information on the severity of OSAS. Thus, we were unable to evaluate whether patients with more severe OSAS had a higher odds ratio for glaucoma than those with milder OSAS.

In recent years, OSAS has been increasingly recognized as a risk factor for both systemic and ocular diseases. For example, past studies have demonstrated that the risks of developing diabetes, stroke, hypertension, and atherosclerosis are increased in OSAS patients \[[@pone.0115625.ref005],[@pone.0115625.ref043],[@pone.0115625.ref044]\]. In ophthalmology, besides glaucoma, papill edema, non-arteritic ischemic optic neuropathy (NAION), and other ocular disorders have also been considered as potential lesions due to intermittent nocturnal hypoxia caused by OSAS \[[@pone.0115625.ref004],[@pone.0115625.ref045],[@pone.0115625.ref046]\]. Based on previous results, combined with this study, it is important for ophthalmologists, otolaryngologists, and sleep physicians to better understand this relationship, so that both relevant ocular disorders and sleep apnea can be recognized and diagnosed and treated early.

Conclusions {#sec017}
===========

In conclusion, this is the first reported meta-analysis with the aim of understanding the association between OSAS and glaucoma. This meta-analysis of six case-control and nine cross-sectional studies confirmed a statistically significant association between OSAS and glaucoma, consistent with a previous retrospective cohort study. Prospective cohort studies that take into consideration potential confounders, or include data from interventional trials to determine whether a reduction in OSAS status is associated with a reduced incidence of glaucoma are needed to clarify whether OSAS is an independent risk factor for glaucoma.
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